Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over: A Multicentric, Randomized, Controlled, Open-label Clinical Trial (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over: A Multicentric, Randomized, Controlled, Open-label Clinical Trial (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. It is the most common cause of neurological disability in young adults, involving a long-term therapeutic follow-up. 85% of the patients are diagnosed with Relapsing-Remitting form of MS (RRMS). This form is characterized by clearly defined acute or subacute neurological symptoms (relapses) followed by periods of partial to complete recovery.
Disease-modifying therapies (DMT) used to treat RRMS are immunomodulatory or suppressor molecules which have proven efficacy in limiting disease activity (decreasing relapse rate and delaying time to disease progression).
However, the long-term safety of DMT is uncertain, as there is an increased risk of developing adverse events or infections (sometimes severe) such as observed in the last pandemic of COVID-19 (higher risk of infection), highlighting the need to reassess the benefit/risk ratio of maintaining immunomodulatory or suppressive therapy in the MS population. In elderly patients with comorbidity, this risk is further increased. To date, few studies on the discontinuation of treatment in elderly RRMS patients have been conducted. However, those available demonstrate that there was no difference in relapse rates between patients who continued or discontinued treatment. These results are consistent with immunosenescence studies in RRMS that suggested a negative correlation between relapse rate/inflammatory processes and age. On the contrary, there is evidence indicating a positive correlation between age and the number of infections.
In addition, in the current context in France, it is important to take into account the medico-social cost associated with long-term treatments. In France, the average estimated annual cost per patient is 12,000€, more than half of which is attributed to medications.Furthermore, with age progression, an inversion of the benefit/cost assessment has been observed in treated patients.
Considering these medical and medico-social factors, it is reasonable to question the value of continuing treatment in stable patients with RRMS over 55 years.
This is a randomized, controlled, multicentric, open-label, parallel groups, 1:1 ratio non-inferiority clinical trial, comparing (1) a group that will stop treatment, to (2) a group that will continue treatment, over the course of 2 years, to determine the survival rate without MS activity defined clinically or by imaging.
The patients in both arms will be followed over 2 years after randomization. 5 visits will be performed for all patients: inclusion/randomization visit (M0) and 4 follow-up visits every 6 months (M6, M12, M18, and M24). An additional phone call at M3 is planned.
Inclusion Criteria:
Patient (male or female) aged 55 and over
RRMS diagnosis according to revised McDonald 2017 criteria
First MS symptom >5 years ago. If the date is unknown, RRMS diagnosis >5 years ago
Stable disease in the last 5 years according to the revised Lublin and Reingold classification characterized by :
Stable T2 lesions documented by MRI performed at least 5 years prior to inclusion versus MRI performed within 6 months prior to the inclusion visit, AND Stable EDSS documented at least 5 years prior to inclusion versus EDSS documented within 6 months prior to inclusion visit, according to the investigator's judgment, AND The absence of relapses within 5 years prior to the inclusion visit
Treated with a Moderate Efficacy Therapy (MET) for at least 5 consecutive years (IFN-β, glatiramer acetate, dimethyl fumarate, teriflunomide, diroximel fumarate); switching from one first-line treatment to another is accepted if the reason for the change is related to personal convenience or intolerance to the first treatment.
Patient with affiliation to a social security regimen
Patient able to understand the objectives and risks associated with the research and to give informed consent to the study
Patient willing and able to comply with study procedures for the duration of the study
Exclusion Criteria:
Primary progressive or secondary progressive with or without relapse as defined by the revised Lublin and Reingold classification
Previous or ongoing treatment with a High Efficacy therapy (HET), with the exception of induction therapy (mitoxantrone, stem cell transplantation, alemtuzumab) provided that the last administration took place at least 10 years prior to inclusion.
Contraindication to MRI (claustrophobia, weight ≥ 140 kg, pacemaker, cochlear implants, foreign body in eye, intracranial vascular clips, surgery in the 6 weeks prior to the beginning of the study, coronary stent implanted in the 8 weeks prior to the beginning of the study,…).
NB : Gadolinium contraindication will not prevent recruitment of the patient; in this case MRI will be carried out without contrast product injection
History of neurological disease affecting the central nervous system: hereditary degenerative CNS disease, degenerative cognitive disease, systemic autoimmune disease, sarcoidosis, Lyme disease…
Chronic disease which requires chronic treatment with corticoids or immunosuppressors
Uncontrolled cardiac, renal or hepatic disease
Patient participating in another interventional trial (drug or a medical device) or patient who are still within an exclusion period
Patient wishing to discontinue background therapy, whether or not they are experiencing adverse effects.
Patient not considering discontinuing background therapy, whether or not they are experiencing adverse effects.
Pregnant or breastfeeding woman
Patient with difficulty to read or understand French,
Patient subject to a legal protection measure
dpidrci@chru-strasbourg.fr03 3 88 11 54 15 ext. 00 33
Bordeaux, 33076, France
aurelie.ruet@chu-bordeaux.fr05 56 79 55 21 ext. +33 (0)
Lille, 59020, France
Marseille, 13005, France
branger-p@chu-caen.fr(0) 2 31 06 46 17 ext. 00 33
pclavelou@chu-clermontferrand.fr(0)4 73 75 07 50 ext. 00 33
alain.creange@aphp.fr01 49 81 23 15 ext. +33 (0)
thibault.moreau@chu-dijon.fr(0)3 80 29 55 84 ext. 00 33
eric.manchon@ch-gonesse.fr(0)1 34 53 21 21 ext. 00 33
cicoclitu@chu-grenoble.fr04 76 76 58 71 ext. +33 (0)
kwiatkowski.arnaud@ghicl.net03 20 87 49 01 ext. +33 (0)
h-zephir@chru-lille.fr(0)3 20 44 68 46 ext. 33
maxime.merindol@chu-limoges.fr(0)5 55 05 65 68 ext. 00 33
bertrand.AUDOIN@ap-hm.fr(0)4 91 38 59 34 ext. 00 33
x-ayrignac@chu-montpellier.fr(0)467337413 ext. 00 33
G.MATHEY@chru-nancy.fr03 83 85 16 88 ext. +33 (0)
Cohen.m@chu-nice.fr04 92 03 79 01 ext. 00 33
eric.thouvenot@chu-nimes.fr04 66 68 32 61 ext. +33 (0)
elisabeth.maillart@ahp.fr01 42 17 62 05 ext. 00 33
cbensa@for.paris(0)1 48 03 68 52 ext. 00 33
laure.michel@chu-rennes.fr(0)299284266 ext. 00 33
bertrand.bourre@chu-rouen.fr(0)2 32 88 58 11 ext. 00 33
david.laplaud@chu-nantes.fr(0)2 40 16 52 12 ext. 00 33
laura.droctove@chru-strasbourg.fr
I.DOGHRI@chu-tours.fr02 47 47 37 22 ext. +33 (0)